FREQUENCY OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN DIABETIC INDIVIDUALS USING NON-INVASIVE SCORE.
DOI:
https://doi.org/10.71000/958n0196Keywords:
body mass index; diabetes mellitus, type 2; Fatty Liver Index; metabolic dysfunction-associated steatotic liver disease; ultrasonographyAbstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in people with type 2 diabetes mellitus and may progress to clinically important liver disease. The Fatty Liver Index (FLI) is a simple non-invasive score derived from routinely available anthropometric and biochemical variables and may help identify hepatic steatosis when imaging is not immediately available.
Objective: To determine the frequency of steatotic liver disease in patients with type 2 diabetes mellitus using the FLI, evaluate its diagnostic performance against abdominal ultrasonography, and identify demographic, anthropometric, and biochemical factors associated with ultrasound-confirmed steatosis.
Methods: This hospital-based cross-sectional observational study included 124 consecutive patients with type 2 diabetes mellitus attending the diabetic clinics and Medical Outpatient Department of Jinnah Postgraduate Medical Centre, Karachi, from mid-March 2026 to mid-June 2026. Demographic, clinical, anthropometric, and biochemical data were collected using a structured proforma. The FLI was calculated from body mass index, waist circumference, triglycerides, and gamma-glutamyl transferase. Abdominal ultrasonography was used as the reference standard for hepatic steatosis. Diagnostic performance was evaluated using sensitivity, specificity, predictive values, diagnostic accuracy, Cohen’s kappa, and receiver operating characteristic analysis. Multivariable binary logistic regression was used to identify independent predictors of ultrasound-confirmed steatosis.
Results: The mean age was 50.00 ± 10.31 years, and 71.0% of participants were female. Ultrasound-confirmed hepatic steatosis was present in 88 participants (71.0%), whereas 77 (62.1%) had FLI ≥60. At this threshold, sensitivity was 73.9%, specificity 66.7%, positive predictive value 84.4%, negative predictive value 51.1%, and overall diagnostic accuracy 71.8%. Agreement with ultrasonography was fair (Cohen’s kappa = 0.372, p < 0.001), and the area under the receiver operating characteristic curve was 0.776. Participants with steatosis had significantly higher body mass index, waist circumference, alanine aminotransferase, and gamma-glutamyl transferase levels. In multivariable analysis, body mass index was the only independent predictor of steatosis (adjusted OR 1.270, 95% CI 1.121–1.438; p < 0.001).
Conclusion: Hepatic steatosis was common in this hospital-based sample of patients with type 2 diabetes mellitus. The FLI showed acceptable discrimination and a high positive predictive value, but its modest sensitivity and low negative predictive value indicate that an FLI <60 should not be used alone to exclude steatosis. Body mass index was independently associated with ultrasound-confirmed steatosis.
Keywords: body mass index; diabetes mellitus, type 2; Fatty Liver Index; metabolic dysfunction-associated steatotic liver disease; ultrasonography
References
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi:10.1097/HEP.0000000000000004.
Younossi ZM, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44(4):1061–1070. doi:10.1111/liv.15852.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. doi:10.1097/HEP.0000000000000520.
Şahintürk Y, et al. Metabolic dysfunction-associated fatty liver disease and fibrosis status in patients with type 2 diabetes treated at internal medicine clinics: Türkiye DAHUDER awareness of fatty liver disease (TR-DAFLD) study. Turk J Gastroenterol. 2024;35(8):643–650. doi:10.5152/tjg.2024.24045.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi:10.1186/1471-230X-6-33.
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031.
Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362–373. doi:10.1016/S2468-1253(19)30383-8.
Pennisi G, Enea M, Falco V, et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol. 2023;21(5):1293–1302.e5. doi:10.1016/j.cgh.2022.06.013.
Malandris K, et al. Diagnostic accuracy of Agile-4 score for liver cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of diagnostic test accuracy studies. Diabetes Obes Metab. 2025;27(3):1406–1414. doi:10.1111/dom.16142.
Tavaglione F, et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023;21(6):1523–1532.e1. doi:10.1016/j.cgh.2022.03.044.
Vamja R, Vala V, Ramachandran A, Nagda J, et al. Diagnostic accuracy of fatty liver index (FLI) for detecting metabolic associated fatty liver disease (MAFLD) in adults attending a tertiary care hospital: a cross-sectional study. Clin Diabetes Endocrinol. 2024;10(1):46. doi:10.1186/s40842-024-00197-2.
Cuthbertson DJ, et al. Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes. Metabolism. 2025;170:156306. doi:10.1016/j.metabol.2025.156306.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi:10.1097/HEP.0000000000000323.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659–689. doi:10.1016/j.jhep.2021.05.025.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–562. doi:10.1016/j.eprac.2022.03.010.
Chong SE, et al. Validation of the Hepamet fibrosis score in a multi-ethnic Asian population. Ann Hepatol. 2023;28(2):100888. doi:10.1016/j.aohep.2022.100888.
Hadadi I, et al. Exploring the prevalence and coexistence of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus patients using ultrasound: a cross-sectional study. Curr Med Imaging. 2025;21:e15734056354807. doi:10.2174/0115734056354807241217043210.
Forlano R, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community: cost effectiveness of screening strategies. Liver Int. 2024;44(1):61–71. doi:10.1111/liv.15730.
Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471–478. doi:10.1016/j.jhep.2022.11.010.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr Hiba Khairat Rizvi, Dr Zeeshan Ali, Dr Marium Fatima Waqar, Dr Ayesha Jameel, Dr Rija Shadab Rizvi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
